Ezogabine Decreases Motor Neuron Excitability in ALS Clinical Trial

Actimed Licenses European Rights to ACM-002 for Treating ALS

Actimed Therapeutics has obtained the rights to develop and commercialize ACM-002 (S-oxprenolol) for the treatment of amyotrophic lateral sclerosis (ALS) in Europe, the company announced. The rights, licensed from patent owner Charité University Medicine Berlin, cover all major European markets, including France, Germany, the U.K., Italy,…

A Physical Presence in Our Lives

On Saturday morning, I lay cuddled next to my husband, Todd, in bed. I could feel his thigh muscles pulse against my leg, misfire after misfire. I wished I could will the fasciculations to stop. When I washed him and changed his shorts, I was struck by how thin his…